American Society of Hirudotherapy

Direct thrombin inhibitors fail to reverse the negative effects of heparin on lung growth and function after murine left pneumonectomy

Research article published in American journal of physiology. Lung cellular and molecular physiology (2024)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportSalivary PharmacologyTsikis et al. · American journal of physiology. Lung cellular and molecular physiology, 2024

Abstract

Neonates with congenital diaphragmatic hernia (CDH) frequently require cardiopulmonary bypass and systemic anticoagulation. We previously demonstrated that even subtherapeutic heparin impairs lung growth and function in a murine model of compensatory lung growth (CLG). The direct thrombin inhibitors (DTIs) bivalirudin and argatroban preserved growth in this model. Although DTIs are increasingly used for systemic anticoagulation clinically, patients with CDH may still receive heparin. In this experiment, lung endothelial cell proliferation was assessed following treatment with heparin-alone or mixed with increasing concentrations of bivalirudin or argatroban. The effects of subtherapeutic heparin with or without DTIs in the CLG model were also investigated. C57BL/6J mice underwent left pneumonectomy and subcutaneous implantation of osmotic pumps. Pumps were preloaded with normal saline, bivalirudin, or argatroban; treated animals received daily intraperitoneal low-dose heparin. In vitro, heparin-alone decreased endothelial cell proliferation and increased apoptosis. The effect of heparin on proliferation, but not apoptosis, was reversed by the addition of bivalirudin and argatroban. In vivo, low-dose heparin decreased lung volume compared with saline-treated controls. All three groups that received heparin demonstrated decreased lung function on pulmonary function testing and impaired exercise performance on treadmill tolerance testing. These findings correlated with decreases in alveolarization, vascularization, angiogenic signaling, and gene expression in the heparin-exposed groups. Together, these data suggest that bivalirudin and argatroban fail to reverse the inhibitory effects of subtherapeutic heparin on lung growth and function. Clinical studies on the impact of low-dose heparin with DTIs on CDH outcomes are warranted.NEW & NOTEWORTHY Infants with pulmonary hypoplasia frequently require cardiopulmonary bypass and systemic anticoagulation. We investigate the effects of simultaneous exposure to heparin and direct thrombin inhibitors (DTIs) on lung growth and pulmonary function in a murine model of compensatory lung growth (CGL). Our data suggest that DTIs fail to reverse the inhibitory effects of subtherapeutic heparin on lung growth and function. Clinical studies on the impact of heparin with DTIs on clinical outcomes are thus warranted.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansAnimalsMiceHeparinAntithrombinsAnticoagulantsPneumonectomyDisease Models, AnimalMice, Inbred C57BLHirudinsFibrinolytic AgentsLung

Summary

Peer-reviewed research on leech salivary compounds and their pharmacology relevant to anticoagulation and antithrombotic therapy. Indexed in PubMed and verified against the NCBI record.

Why This Matters for Hirudotherapy

In this murine compensatory lung-growth model relevant to congenital diaphragmatic hernia, even subtherapeutic heparin impaired lung growth, vascularization, and function, and the direct thrombin inhibitors bivalirudin and argatroban failed to reverse heparin's inhibitory effects in vivo (though they did rescue endothelial cell proliferation in vitro). The hirudotherapy connection runs through the thrombin-inhibitor class itself: the study is indexed under Hirudins, and the medicinal leech is the original natural source of direct thrombin inhibition (hirudin), so this work informs the wider pharmacology and limits of thrombin-axis anticoagulants. The honest caveat is that this is a preclinical mouse study of synthetic DTIs combined with heparin, not a leech or hirudin study and not a clinical trial; the authors themselves note that human clinical studies are still warranted, so it should not be generalized to leech therapy or to patients.

Citation

Direct thrombin inhibitors fail to reverse the negative effects of heparin on lung growth and function after murine left pneumonectomy.

Tsikis et al. · American journal of physiology. Lung cellular and molecular physiology, 2024

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.